BFRI News and Press, Biofrontera Inc. From 11/30/22

WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmark’s 11th Annual Discovery One-on-One I...

Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on ...

WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clini...

Biofrontera, Inc. (BFRI) Q3 2022 Earnings Conference Call November 14, 2022, 11:00 ET Company Participants Tirth Patel - LHA Investor Relations Fred Leffler - CFO Erica Monaco - CEO, COO, Treasurer & Secretary Conference Call Participants Jonathan...

Biofrontera press release ( NASDAQ: BFRI ): Q3 GAAP EPS of -$0.11 beats by $0.18 . Revenue of $4.32M (-0.2% Y/Y) beats by $0.01M . As of September 30, 2022, Biofrontera had cash and cash equivalents of $27.5M, compared with $24.5M as of December 31, 2021. T...

Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for t...

WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 b...

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the exercise in full of options to purchase 2,623,365 ordinary shares of Biofronter...

Sets company up to realize full commercial potential in fast growing U.S. market Supports mutually beneficial interests between Biofrontera Inc and Biofrontera AG WOBURN, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical co...

U.S. biopharmaceutical company Biofrontera ( NASDAQ: BFRI ) has appointed Fred Leffler as CFO, with immediate effect. Most recently, Mr. Leffler served as a Senior Manager at McKinsey & Company in Boston. He is an experienced financial executive with 15 years of leader...